Novo Nordisk A/S (NVO) Stock Analysis
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $44.50 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2).
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides... Read more
Sell if holding. Analyst target reached at $44.50 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.4/10, moderate confidence.
Passes 5/9 gates (clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and news legal. Suitability: moderate.
Recent Developments — Novo Nordisk A/S
Latest news
- Novo Nordisk A/S Stock (NVO) Moved Down by 3.07% on Apr 29: Drivers Behind the Movement - TradingKey — TradingKey negative
- Novo Nordisk (NVO) slides as investors refocus on ongoing GLP-1 pricing pressure and softer 2026 outlook - Quiver Quanti — Quiver Quantitative negative
- Novo Nordisk: Misread Q1 Earnings, Mispriced Stock (NYSE:NVO) - Seeking Alpha — Seeking Alpha negative
- NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up - Yahoo Finance Singapore — Yahoo Finance Singapore positive
- Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook - Novo Nordisk (NYSE:NVO) - Benzinga — Benzinga positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $44.50 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $41.56. Score 6.4/10, moderate confidence.
Take-profit target: $46.83 (+5.8% upside). Prior stop was $41.56. Stop-loss: $41.56.
Analyst target reached - limited upside remaining; Consecutive earnings misses (2); Negative momentum.
Novo Nordisk A/S trades at a P/E of 10.4 (forward 13.2). TrendMatrix value score: 7.1/10. Verdict: Sell.
37 analysts cover NVO with a consensus score of 3.4/5. Average price target: $47.
What does Novo Nordisk A/S do?Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and...
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.